XOMA Royalty Corporation (NASDAQ:XOMA) Receives $53.75 Consensus Target Price from Brokerages

XOMA Royalty Corporation (NASDAQ:XOMA) has been assigned an average rating of “Hold” from the seven brokerages that are covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $53.75.

A number of equities research analysts have recently commented on the stock. Lucid Cap Mkts cut shares of XOMA Royalty from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. HC Wainwright cut XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 price objective on the stock. in a research report on Thursday, April 30th. Zacks Research upgraded XOMA Royalty from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 8th. Benchmark lowered XOMA Royalty from a “buy” rating to a “hold” rating in a report on Friday, May 22nd. Finally, Weiss Ratings upgraded XOMA Royalty from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, May 29th.

XOMA Royalty Stock Performance

XOMA Royalty stock opened at $40.17 on Friday. The stock’s 50 day simple moving average is $41.70 and its two-hundred day simple moving average is $35.04. The company has a debt-to-equity ratio of 0.96, a quick ratio of 3.59 and a current ratio of 3.59. The stock has a market cap of $503.77 million, a price-to-earnings ratio of 25.59 and a beta of 0.86. XOMA Royalty has a fifty-two week low of $22.29 and a fifty-two week high of $45.22.

XOMA Royalty (NASDAQ:XOMA) last issued its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02). XOMA Royalty had a net margin of 53.46% and a return on equity of 12.56%. The business had revenue of $12.32 million for the quarter, compared to analysts’ expectations of $13.91 million. As a group, analysts expect that XOMA Royalty will post 0.9 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of XOMA. Russell Investments Group Ltd. lifted its position in XOMA Royalty by 3,436.4% during the third quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 756 shares in the last quarter. State of Alaska Department of Revenue bought a new stake in XOMA Royalty during the fourth quarter valued at about $27,000. Tower Research Capital LLC TRC increased its position in XOMA Royalty by 203.1% in the second quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after buying an additional 1,523 shares in the last quarter. BNP Paribas Financial Markets increased its position in XOMA Royalty by 266.6% in the third quarter. BNP Paribas Financial Markets now owns 3,226 shares of the biotechnology company’s stock worth $124,000 after buying an additional 2,346 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of XOMA Royalty by 13.9% in the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock worth $112,000 after buying an additional 543 shares during the period. Institutional investors own 95.92% of the company’s stock.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.